Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431028 | 1.00 | EPHX2 (0.34) | EPHX2 | |
| SCHEMBL12908665 | 0.85 | CA1 (0.32) | — | |
| SCHEMBL13267995 | 0.85 | — | — | |
| SCHEMBL2683995 | 0.85 | — | — | |
| SCHEMBL7606490 | 0.85 | — | — | |
| SCHEMBL14302491 | 0.78 | ALDH1A1 (0.34) | EPHX2 | |
| SCHEMBL10186334 | 0.77 | — | — | |
| SCHEMBL14431029 | 0.77 | — | — | |
| SCHEMBL12449368 | 0.77 | — | — | |
| SCHEMBL14080228 | 0.77 | EPHX2 (0.44) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | EPHX2 360/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | EPHX2 360/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | EPHX2 360/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | EPHX2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.